This is a significant positive catalyst for SMMT. The strong OS data from HARMONi-2 de-risks the ivonescimab program and supports the ongoing HARMONi-7 global study. Traders should watch for the full data presentation at WCLC on September 15, 2026, and the upcoming PDUFA date of November 14, 2026 for the HARMONi BLA. The stock may see upward momentum as the market prices in improved probability of success for ivonescimab in the first-line NSCLC setting.
Drug in focus
SMMT drug pipeline →ivonescimab
◆ Mixed Named in this 8-K- Impact
- Phase
- Filed/PDUFA (BLA under FDA review); also multiple ongoing Phase 3 trials
- Time to market
- If approved, potential US launch in late 2026 or early 2027. Already approved in China (May 2024).
- Next catalyst
- None dated
What to watchThe November 14 PDUFA is the defining event. The HARMONi global trial showed statistically significant PFS but OS missed the pre-specified threshold, an unusual situation that creates binary risk on approval odds. Watch for an FDA Advisory Committee date (if scheduled) as a pre-decision signal. Also watch HARMONi-3 final PFS readout (2H 2026) as a secondary catalyst. The $500M June offering diluted existing holders but extended the cash runway, and the massive insider buying (~$100M from co-CEOs at ~$13.12) signals conviction at current levels.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 14 $18.42entry
- T+1 · 2mo ago −5.54%α −5.08% · $17.40
- T+5 · 8w ago −8.25%α −8.36% · $16.90
- T+20 · 5w ago −7.00%α −9.27% · $17.13
- T+45 · todayOpen
- T+60 · in 21d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Summit Therapeutics announced via 8-K that its partner Akeso presented updated overall survival (OS) data from the Phase III HARMONi-2 trial of ivonescimab vs. pembrolizumab in PD-L1-positive advanced NSCLC at WCLC 2026. Ivonescimab demonstrated a statistically significant 27% reduction in the risk of death (HR 0.73, p=0.009) with a median OS improvement of 8.2 months (30.8 vs 22.6 months), including a strong HR of 0.58 in the PD-L1 high subgroup. This is a major positive catalyst for Summit's ivonescimab program and supports the ongoing global Phase III HARMONi-7 study, though ivonescimab remains unapproved in Summit's license territories (US, Europe).
Key Facts
- Ivonescimab reduced risk of death by 27% vs pembrolizumab (HR 0.73; 95% CI 0.57-0.95; p=0.009) in HARMONi-2 Phase III trial.
- Median OS was 30.8 months for ivonescimab vs 22.6 months for pembrolizumab, an 8.2-month improvement.
- In PD-L1 high expression subgroup (score ≥50%), HR was 0.58 (95% CI 0.38-0.89).
- HARMONi-2 is the fourth Phase III study of ivonescimab to show statistically significant improvements in both OS and PFS vs standard of care.
- Summit is conducting the global Phase III HARMONi-7 study (target 780 patients) evaluating ivonescimab monotherapy vs pembrolizumab in PD-L1 high-expressing metastatic NSCLC.
- Ivonescimab remains investigational and not approved by any regulatory authority in Summit's license territories (US, Europe).
- Akeso received NMPA marketing authorization in China for ivonescimab based on HARMONi-2 results in April 2025.
- Summit's BLA for ivonescimab in EGFR-mutated NSCLC (HARMONi study) was accepted by FDA with PDUFA date of November 14, 2026.
Financial Impact
No financial figures reported in filing. Positive OS data strengthens ivonescimab's commercial prospects and supports Summit's $14B market cap. Key catalyst for HARMONi-7 global study and potential US/EU regulatory filings.
Risk Factors
- Ivonescimab is not yet approved in US or Europe; regulatory risk remains.
- HARMONi-2 was a single-region (China) study; global HARMONi-7 results may differ.
- Competition from existing PD-1 inhibitors and other bispecific antibodies in development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001599298-26-000078 |
| Document: a2026_prx0913xharmoni-2o.htm | 0001599298-26-000078 |
| Document: 0001599298-26-000078-index-headers.html | 0001599298-26-000078 |
| Document: 0001599298-26-000078-index.html | 0001599298-26-000078 |
| Document: 0001599298-26-000078.txt | 0001599298-26-000078 |
Track record
23 reports on SMMT
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +23.34% at T+60 after the Jun 12, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 16, 2026today 8-K Bearish 7/10 Entry $11.43 Now $11.82 −3.41% settles Nov 17
- Nov 4, 202612d ago 8-K Neutral 3/10 Entry $14.19 to $16.33 Now $11.82 −16.70% ▲ +15.08% +14.77% vs SPY
- Nov 4, 202612d ago 8-K Neutral 6/10 Entry $14.19 to $16.33 Now $11.82 −16.70% ▲ +15.08% +14.77% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $16.17 to $14.19 Now $11.82 −26.90% ▼ −12.24% −7.84% vs SPY
- Oct 21, 202626d ago Press Release Neutral 5/10 Entry $15.83 to $15.55 Now $11.82 −25.33% ▼ −1.77% −0.59% vs SPY
- Oct 19, 202628d ago DEF 14A Neutral 5/10 Entry $15.57 to $16.09 Now $11.82 −24.08% ▲ +3.34% +3.00% vs SPY
- Sep 28, 20267w ago 8-K Bullish 8/10 Entry $16.39 to $16.91 Now $11.82 −27.88% ▲ +3.17% +3.38% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Entry $17.40 to $17.54 Now $11.82 −32.07% ▲ +0.80% +0.48% vs SPY
- Sep 14, 20269w ago 8-K Bullish 7/10 Viewing Entry $18.42 to $17.40 Now $11.82 −35.83% ▼ −5.54% −5.08% vs SPY
- Sep 3, 202610w ago 8-K Bullish 6/10 Entry $17.13 to $17.61 Now $11.82 −31.00% ▲ +2.77% +3.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers